MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17

Luo, Moulun; Sun, Gang; Sun, Junyan

doi:10.1016/j.anl.2018.10.020

Cited by 27 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overexpression of miR-196a has been shown to significantly increase cell proliferation, migration, and invasion, and to induce EMT, possibly through targeting of ANXA1 [ 173 ] and MAMDC2 [ 174 ] in HNSCC cells, and of HOXB8 and p27 (CDKN1B) in OSCC cells [ 175 ]. MiR-196b has been demonstrated to promote cell proliferation and invasion, and to suppress apoptosis by targeting SOCS2 [ 176 ] and PCDH-17 [ 177 ] in LSCC cells and ANXA1 in HNSCC cells [ 178 ]. The combined detection of plasma miR-196a and miR-196b expression appears highly potent in diagnosing oral cancer patients with high sensitivity and specificity [ 171 ].…”

Section: The Role Of the Most Common Mirnas In Hncmentioning

confidence: 99%

“…It has also been highlighted as a promising marker of HNSCC response to radiotherapy, since miR-196a overexpression appears to increase radioresistance in HNSCC cells [ 173 ]. Notably, both miR-196a and miR-196b have been characterized as potentially important therapeutic targets, since the inhibition of these miRNAs has been shown to reduce cell proliferation in oral cancer and LSCC cell lines [ 175 , 177 , 180 ]. Furthermore, both miR-196a and miR-196b have been suggested as promising diagnostic, prognostic, and therapeutic biomarkers for LC.…”

Section: The Role Of the Most Common Mirnas In Hncmentioning

confidence: 99%

See 1 more Smart Citation

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

Thomaidou

Batsaki

Adamaki

et al. 2022

IJMS

View full text Add to dashboard Cite

Head and neck cancers (HNCs) comprise a heterogeneous group of tumors that extend from the oral cavity to the upper gastrointestinal tract. The principal etiologic factors for oral tumors include tobacco smoking and alcohol consumption, while human papillomavirus (HPV) infections have been accused of a high incidence of pharyngeal tumors. Accordingly, HPV detection has been extensively used to categorize carcinomas of the head and neck. The diverse nature of HNC highlights the necessity for novel, sensitive, and precise biomarkers for the prompt diagnosis of the disease, its successful monitoring, and the timely prognosis of patient clinical outcomes. In this context, the identification of certain microRNAs (miRNAs) and/or the detection of alterations in their expression patterns, in a variety of somatic fluids and tissues, could serve as valuable biomarkers for precision oncology. In the present review, we summarize some of the most frequently studied miRNAs (including miR-21, -375, -99, -34a, -200, -31, -125a/b, -196a/b, -9, -181a, -155, -146a, -23a, -16, -29, and let-7), their role as biomarkers, and their implication in HNC pathogenesis. Moreover, we designate the potential of given miRNAs and miRNA signatures as novel diagnostic and prognostic tools for successful patient stratification. Finally, we discuss the currently ongoing clinical trials that aim to identify the diagnostic, prognostic, or therapeutic utility of miRNAs in HNC.

show abstract

Section: The Role Of the Most Common Mirnas In Hncmentioning

confidence: 99%

Section: The Role Of the Most Common Mirnas In Hncmentioning

confidence: 99%

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

Thomaidou

Batsaki

Adamaki

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…miRNAs negatively modulate the expression of cancer-associated genes, and thus regulate cancer progression ( 16 , 17 ). Aberrant expression of miRNAs has been reported in LSCC, and is associated with angiogenesis, tumor growth and metastasis ( 18 – 20 ). For example, miR-143-3p suppresses the proliferation and invasion of LSCC cells by targeting melanoma-associated antigen A9 ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

miR‑375‑3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor‑1β

2020

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is one of the most frequently diagnosed head and neck cancers worldwide. Increasing evidence suggests that microRNAs (miRNAs/miRs) regulate the progression of tumorigenesis and the malignant behaviors of cancer cells. The aim of this study was to investigate the function and underlying mechanism of miR-375-3p in LSCC. The expression of miR-375-3p in LSCC tissues and cells was detected using reverse transcription-quantitative PCR. The effects of miR-375-3p on the malignant phenotype of LSCC cells was determined using the Cell Counting Kit-8 assay and flow cytometry. The targets of miR-375-3p were predicted using the miRDB database and confirmed by the luciferase reporter assay. The results of the present study demonstrated that miR-375-3p was downregulated in LSCC tissues and cell lines. Furthermore, overexpression of miR-375-3p significantly suppressed the proliferation and cell cycle progression of LSCC cells. Overexpression of miR-375-3p also increased LSCC cell apoptosis. Mechanistical analysis indicated that miR-375-3p bound the 3'-untranslated region of the hepatocyte nuclear factor 1β (HNF1β) and decreased its expression in LSCC cells. Consistent with the role of HNF1β in glucose metabolism, overexpression of miR-375-3p significantly inhibited glucose consumption and lactate production in LSCC cells. Transfection with HNF1β notably reversed the inhibitory effect of miR-375-3p on the proliferation of LSCC cells. Collectively, these results indicate the tumor suppressive role of miR-375-3p in LSCC via HNF1β, suggesting that miR-375-3p may serve as a potential target in the treatment of LSCC.

show abstract

“…The lack of PCDH17 protein re-expression after AZA + VAL treatment, on the other hand, could be attributed to several factors, including: (a) the low specificity of the primary antibody against the canine protein; (b) the length of the treatment and/or the dose used, which were potentially insufficient for PCDH17 protein re-expression; and (c) the presence of post-transcriptional regulatory mechanisms. In this respect, epigenetic modulation of miR-196b, an oncogenic miRNA discovered in many human malignancies [ 58 , 59 , 60 ] and targeting PCDH17 mRNA [ 61 ] was seen in human leukaemia cells [ 62 ]. As a result, we suggest that the use of epigenetic compounds (i.e., AZA/VAL) activated some post-transcriptional regulatory mechanisms of the PCDH17 protein, neutralizing the expected direct effect of HDs and HDACis on PCDH17 re-expression.…”

Section: Discussionmentioning

confidence: 99%

Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies

Zorzan

Elgendy

Guerra

et al. 2022

IJMS

View full text Add to dashboard Cite

Gene expression is controlled by epigenetic deregulation, a hallmark of cancer. The DNA methylome of canine diffuse large B-cell lymphoma (cDLBCL), the most frequent malignancy of B-lymphocytes in dog, has recently been investigated, suggesting that aberrant hypermethylation of CpG loci is associated with gene silencing. Here, we used a multi-omics approach (DNA methylome, transcriptome and copy number variations) combined with functional in vitro assays, to identify putative tumour suppressor genes subjected to DNA methylation in cDLBCL. Using four cDLBCL primary cell cultures and CLBL-1 cells, we found that CiDEA, MAL and PCDH17, which were significantly suppressed in DLBCL samples, were hypermethylated and also responsive (at the DNA, mRNA and protein level) to pharmacological unmasking with hypomethylating drugs and histone deacetylase inhibitors. The regulatory mechanism underneath the methylation-dependent inhibition of those target genes expression was then investigated through luciferase and in vitro methylation assays. In the most responsive CpG-rich regions, an in silico analysis allowed the prediction of putative transcription factor binding sites influenced by DNA methylation. Interestingly, regulatory elements for AP2, MZF1, NF-kB, PAX5 and SP1 were commonly identified in all three genes. This study provides a foundation for characterisation and experimental validation of novel epigenetically-dysregulated pathways in cDLBCL.

show abstract

MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17

Cited by 27 publications

References 43 publications

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

miR‑375‑3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor‑1β

Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies

Contact Info

Product

Resources

About

MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17

Cited by 27 publications

References 43 publications

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs

miR‑375‑3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor‑1&beta;

Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies

Contact Info

Product

Resources

About

miR‑375‑3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor‑1β